RxDoctor Payments Data

Saba Chughtai, MD

Psychiatry · Mason, OHNPI 1720027824

Payments from drug & device makers

$758in general payments, 2019–2025

Across 52 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$230
  • AbbVie$181
  • Amgen$115
  • Supernus Pharmaceuticals, Inc.$46
  • Almatica Pharma LLC$35
  • Axsome Therapeutics, Inc.$24
  • plus $126 from 8 others

What the payments were for

  • Food & beverage$758100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$758 in reported general payments places this provider in the 65th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$44,111
Medicare patients
60
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine20$119,651
RexultiBrexpiprazole22$29,839
ClozarilClozapine11$27,875
Vilazodone Hcl116$8,876
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine31$3,330
Duloxetine Hcl186$3,164
Aripiprazole61$2,990
Lamotrigine ErLamotrigine14$2,671
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine71$2,238
Bupropion XlBupropion Hcl130$1,971
Olanzapine50$1,870
Lorazepam143$1,328
Escitalopram Oxalate194$1,202
Quetiapine Fumarate98$1,032
Fluoxetine Hcl128$985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$13$119,65120 claims
Otsuka America Pharmaceutical, Inc.Rexulti$13$29,83922 claims
Almatica Pharma LLCSertraline Hcl$35$45380 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Mason

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →